Memory loss is one of the key features of cognitive impairment in either aging, Mild Cognitive Impairment (MCI) or dementia. Pharmacological treatments for memory loss are today focused on addressing symptomatology. One of these approved compounds is memantine, a partial NMDA receptor antagonist that has proved its beneficial effects in cognition. The Octodon degus (O. degus) has been recently proposed as a potential model relevant for neurodegenerative diseases. However, there are no previous studies investigating the effect of pharmacological treatments for age-related cognitive impairment in this rodent. In this work we aimed to evaluate the effect of memantine on sleep deprivation (SD)-induced memory impairment in young and old O. degus...
Hippocampal kindling which have been used to investigate temporal lobe epilepsy can also be used to ...
Memantine is an uncompetitive antagonist with moderate affinity for NMDA receptors, and it demonstra...
Background Prevalence of Alzheimer's disease in people with Down's syndrome is very high, and many s...
The development of novel therapeutics to prevent cognitive decline of Alzheimer's disease (AD) is fa...
International audienceThe development of novel therapeutics to prevent cognitive decline of Alzheime...
Memantine, a drug recently approved for treatment of Alzheimer’s disease, has been characterized as ...
We present data on whether memantine, an adamantane derivative and medical NMDA-receptor antagonist...
International audienceCurrent pharmacotherapies for Alzheimer's disease (AD) are focused on improvin...
Background and Objective: Memantine (MEM) an uncompetitive N-methyl-D-aspartate receptor antagonist ...
We herein present behavioral data on whether memantine, an adamantane derivative and medical NMDA-re...
Chronic treatment of adult male F-344 rats (9-12 months old) with therapeutically relevant doses of ...
Abstract Background Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate recept...
Ts65Dn (TS) mice exhibit several phenotypic characteristics of human Down syndrome, including an inc...
Memantine and neramexane are noncompetitive NMDA receptor antagonists which have been investigated f...
Neurogenesis occurs during the embryological development of the brain. However, it is universally ac...
Hippocampal kindling which have been used to investigate temporal lobe epilepsy can also be used to ...
Memantine is an uncompetitive antagonist with moderate affinity for NMDA receptors, and it demonstra...
Background Prevalence of Alzheimer's disease in people with Down's syndrome is very high, and many s...
The development of novel therapeutics to prevent cognitive decline of Alzheimer's disease (AD) is fa...
International audienceThe development of novel therapeutics to prevent cognitive decline of Alzheime...
Memantine, a drug recently approved for treatment of Alzheimer’s disease, has been characterized as ...
We present data on whether memantine, an adamantane derivative and medical NMDA-receptor antagonist...
International audienceCurrent pharmacotherapies for Alzheimer's disease (AD) are focused on improvin...
Background and Objective: Memantine (MEM) an uncompetitive N-methyl-D-aspartate receptor antagonist ...
We herein present behavioral data on whether memantine, an adamantane derivative and medical NMDA-re...
Chronic treatment of adult male F-344 rats (9-12 months old) with therapeutically relevant doses of ...
Abstract Background Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate recept...
Ts65Dn (TS) mice exhibit several phenotypic characteristics of human Down syndrome, including an inc...
Memantine and neramexane are noncompetitive NMDA receptor antagonists which have been investigated f...
Neurogenesis occurs during the embryological development of the brain. However, it is universally ac...
Hippocampal kindling which have been used to investigate temporal lobe epilepsy can also be used to ...
Memantine is an uncompetitive antagonist with moderate affinity for NMDA receptors, and it demonstra...
Background Prevalence of Alzheimer's disease in people with Down's syndrome is very high, and many s...